Latest news with #HART
Yahoo
3 days ago
- Automotive
- Yahoo
Two rushed to hospital after crash on busy road in London
Two people have been rushed to hospital after a crash on a busy road in London. The London Ambulance Service were called to Piccadilly, W1J, just before 5.30am today (June 29) to reports of a crash. Ambulance crews, a paramedic in a fast response car, an incident response officer, and members of the LAS's hazardous area response team (HART) were dispatched. A trauma team in a car from London's Air Ambulance was also dispatched. The first paramedic arrived on the scene in less than four minutes. Two people were treated, with one patient taken to a major trauma centre, and the other patient to a local hospital. A London Ambulance Service spokesperson said: 'We were called at 5.25am today (29 June) to reports of a road traffic collision on Piccadilly, W1J. 'We sent a number of resources, including ambulance crews, a paramedic in a fast response car, an incident response officer and members of our hazardous area response team (HART). We also dispatched a trauma team in a car from London's Air Ambulance. 'Our first paramedic arrived on scene in less than four minutes. 'We treated two people. We took one patient to a major trauma centre and the other patient to a local hospital.'
Associated Press
25-06-2025
- Health
- Associated Press
Kratom Consumer Advisory Council (KCAC) Releases White Paper Refuting HART's Misleading Claims on Synthetic 'Gas Station Heroin' and Opioid Mortality Rates
'HART's argument isn't just scientifically unsupported—it's dangerous,' stated Dr. C. Michael White, UCONN Kratom Consumer Advisory Council (KCAC) today released a comprehensive position paper, " Fact Check on Synthetic 7 Solving the Opioid Crisis,' refuting the Holistic Alternative Recovery Trust's (HART) claim and that of its National Policy Director Jeff Smith (media clip here ) that synthetic 7-hydroxymitragynine ('synthetic 7') products have reduced the opioid mortality death rate in the United States. This claim, which HART has presented in testimony to lawmakers in multiple states and to media outlets, is not supported by any published clinical trials or peer-reviewed observational studies. In contrast, the KCAC's position paper outlines overwhelming evidence pointing to community naloxone distribution and public health partnerships as the true drivers of reduced opioid deaths. 'HART's argument isn't just scientifically unsupported—it's dangerous,' said Dr. C. Michael White, Pharm.D., FCP, FCCP, FASHP, a pharmacist, distinguished professor of pharmacy practice at the University of Connecticut School of Pharmacy, and KCAC chair. 'The reduction in opioid mortality in recent years correlates most clearly with community-based naloxone access and training initiatives, not the rise of potent, unregulated synthetic opioids being sold in gas stations and smoke shops.' The KCAC white paper highlights well-documented evidence from public health literature: Unlike whole-leaf kratom and natural mitragynine—which preclinical studies suggest have a low risk of respiratory depression—synthetic 7 and similar analogs (including tianeptine and mitragynine pseudoindoxyl) have been shown in multiple animal studies to significantly depress respiratory function at high doses. These effects mirror those of morphine and respond poorly to naloxone reversal—underscoring their danger to public health. Further, anecdotal reports suggest that synthetic 7 products have caused severe addiction, and the rapid tolerance requires consumers to escalate doses over time. In addition, their bright packaging and candy-like branding (e.g., 'Perks,' 'Opia,' 'Rave') may appeal to children and teens—raising additional concerns among parents and policymakers. Leading kratom researchers at Johns Hopkins University and the University of Florida have issued urgent warnings about the proliferation of 7 products and their potential for abuse, dependence, severe withdrawal, and even respiratory depression —dangers that run directly counter to it being marketed as a treatment for opioid addiction. A leading forensic research center has published public alerts on 7 products. Dr. White cautions, 'Selling potent opioid receptor-stimulating 7 products in gas stations, convenience stores, and smoke shops in unlimited quantities within arm's reach of candy bars and energy drinks is a public health recipe for disaster. It allows a whole new generation of consumers to potentially get hooked on opioids, and we know where that leads.' The KCAC's position papers in total provide lawmakers a roadmap based on the best available published evidence to protect consumers while still maintaining access to natural kratom products and runs counter to unsubstantiated pseudo-scientific claims. Download the full position paper here. About Kratom Consumer Advisory Council (KCAC) Kratom Consumer Advisory Council (KCAC) is an independent board made up of a clinician-scientist and consumers that uses the strongest available evidence to produce position statements that promote evidence-based policy. The KCAC is supported by the Global Kratom Coalition which advocates for regulations that protect consumers and curbs the sale of adulterated or synthetic products falsely marketed as kratom. For more information, visit Media Contact Dr. C. Michael White [email protected] ### SOURCE: Kratom Consumer Advisory Council (KCAC) Copyright 2025 EZ Newswire
Business Wire
10-06-2025
- Business
- Business Wire
Prevencio Awarded U.S., European and Japanese Patents for HART CADhs, Its AI-Driven Blood Test for Coronary Artery Disease
KIRKLAND, Wash.--(BUSINESS WIRE)-- Prevencio, Inc., the leader in artificial intelligence-powered blood tests for cardiovascular disease, today announced that it has been granted patents for its HART CADhs® test in the United States—marking the second U.S. patent for this novel test—as well as the European Union and Japan. These patents protect Prevencio's proprietary methods and algorithms for detecting obstructive coronary artery disease (CAD) using a multi-protein, AI-driven blood test platform. The newly issued patents strengthen Prevencio's intellectual property portfolio and support its long-term strategy to expand HART CADhs adoption globally. HART CADhs is the only blood test that combines multiple cardiac proteins with machine learning to deliver a highly accurate, non-invasive diagnosis of obstructive CAD. 'Securing patent protection in the U.S., Europe, and Japan marks a major step forward in advancing our innovation and market leadership,' said Rhonda Rhyne, Chief Executive Officer of Prevencio. 'These patents reinforce the uniqueness of our HART CADhs test and underscore our commitment to improving cardiovascular diagnostics worldwide.' Prevencio is redefining the future of cardiovascular diagnostics. With two marketed, AI-driven blood tests—HART CADhs and HART CVE—and bolstered by international patent protection, compelling clinical data, reimbursement, and recent FDA Breakthrough Device Designation, Prevencio uniquely delivers a convergence of innovation, validation, and commercial readiness. 'Cardiovascular disease is a global problem. International patent protection will help Prevencio to deliver scalable solutions that meet urgent diagnostic needs in the U.S. as well as global markets,' said James L. Januzzi, MD, a practicing cardiologist at MGH, Professor of Medicine at Harvard Medical School, Chief Scientific Officer at the Baim Institute for Clinical Research and Principal Investigator for the HART test development and validation. Cardiovascular disease remains the leading cause of death worldwide and accounts for more than $318 billion in annual U.S. healthcare costs, nearly 10% of total healthcare spending. Prevencio's HART blood tests are designed to improve accessibility, accuracy, and patient outcomes while reducing costs through earlier, more accessible, and accurate blood diagnostics. Both HART CADhs and HART CVE, a second AI-driven, multi-protein blood test that assesses a patient's one-year risk of heart attack, stroke, or cardiovascular death, are currently available to healthcare providers and for research use. About Prevencio, Inc. Prevencio is transforming cardiovascular care through AI-driven blood tests that deliver earlier, accurate, and more accessible diagnostics. The company's HART platform powers the development of proprietary tests for cardiovascular disease, including HART CADhs® for detecting obstructive coronary artery disease and HART CVE® for assessing one-year risk of heart attack, stroke, or cardiovascular death. For more information, visit Forward-Looking Statement: Except for historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which is subject to various uncertainties of early stage companies. The company does not undertake to update disclosures contained in this press release.
CBC
09-06-2025
- Health
- CBC
Homelessness and addiction hubs in Sault Ste. Marie and Sudbury face delays opening
Social Sharing Treatment (HART) hubs in northeastern Ontario are still waiting for final approvals from the province to start operating. On the eve of the provincial election, Ontario Health Minister Sylvia Jones announced 19 new HART hubs would be operational by April 1. The hubs would provide access to recovery and treatment systems for people struggling with addictions and mental health issues, but would not provide any safe drug consumption services. Lisa Case is the CEO of the Canadian Mental Health Association (CMHA) Algoma, which was chosen to run the HART hub in Sault Ste. Marie. She said the organization has submitted its budget with the province for the planned hub. Ontario's Ministry of Health and Ontario Health have reviewed that submission, Case said, but now she's waiting for additional feedback. "We have received updated terms and conditions related to that funding that we're reviewing with our partners and responding with some additional questions, but we're still in that holding pattern right now," Case said. She said the province has allocated CMHA Algoma a budget of $6.31 million annually over three years to run its HART hub. Case added the services are especially needed in northern Ontario. "We've been hit harder across the north in spite of the creativity that we've used as community partners and the interventions we're able to provide," she said. "We're seeing just the volumes of individuals seeking help and then often the distance to get help." The City of Greater Sudbury will run a HART Hub in collaboration with the Health Sciences North hospital. The city says it's still finalizing logistical details but should have more concrete information to share by next week. Ema Popovic, a spokesperson for Ontario's health minister, said in an email to CBC News that nine HART hubs in the province that were previously supervised drug consumption sites opened on April 1. That includes the NorWest Community Health Centre in Thunder Bay.
Yahoo
08-06-2025
- Business
- Yahoo
Officials expect federal funding to continue for Honolulu rail project
The city's rail project has a 'binding contract ' to continue to receive federal funding despite the Trump administration's threat to pull an estimated $4 billion from California's high-speed train project. U.S. Sen. Brian Schatz, D-Hawaii, said in a statement that the so-called full-funding grant agreement between Honolulu's rail project and the Federal Transit Administration 'is a binding contract between the FTA and the City and County of Honolulu.' 'We expect both parties to continue to adhere to the provisions within the contract, ' Schatz said. 'We will continue to work with the FTA and the City to make sure the milestones are met and the remaining federal funding is obligated as outlined in the FFGA.' Since 2017, the FTA had withheld $744 million in rail funding following years of construction delays and skyrocketing budgets. The federal financial spigot finally turned on in 2024 after the route was cut by two stations, rail service began in 2023 and the state Legislature allowed each county to charge a new 3 % hotel room tax, which Oahu now uses, in part, to ensure a flow of city funds for its Skyline rail project. After the first payment of $125 million arrived in April 2024, HART received an additional $250 million Aug. 15 by awarding the construction contract on the final planned half-mile, overhead rail segment and City Center station in Kakaako, said Lori Kahikina, HART's CEO and executive director. 'At this time there are no concerns regarding the remaining federal funding committed through the amended Full Funding Grant Agreement, ' Kahikina said in a written statement. 'HART continues to have strong relationships with our Hawaii congressional delegation and the Federal Transit Administration, and will continue to work closely with them on matters pertaining to the rail project.'—RELATED : She expects another $125 million by completing the rail station and guideway at Daniel K. Inouye International Airport, followed by another $125 million after completing HART's utility relocation project for the City Center station and guideway, followed by an additional $119 million in fiscal year 2027. The full 19-station, 18.9 mile route from East Kapolei to the Civic Center station in Kakaako is scheduled for completion in 2031. The acting head of the Federal Railroad Administration last week wrote California's high-speed rail authority that it should expect to lose its $4 billion in federal funding following years of delays and billions in cost overruns.
